CN115466689B - Probiotic composition for preventing and/or treating metabolic diseases and application thereof - Google Patents
Probiotic composition for preventing and/or treating metabolic diseases and application thereof Download PDFInfo
- Publication number
- CN115466689B CN115466689B CN202210122665.4A CN202210122665A CN115466689B CN 115466689 B CN115466689 B CN 115466689B CN 202210122665 A CN202210122665 A CN 202210122665A CN 115466689 B CN115466689 B CN 115466689B
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- probiotic composition
- faecalis
- mice
- cctcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 65
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 65
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 27
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 42
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 238000004321 preservation Methods 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 17
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 12
- 241001608472 Bifidobacterium longum Species 0.000 claims description 12
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 12
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 235000013406 prebiotics Nutrition 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 24
- 239000008103 glucose Substances 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 14
- 210000002966 serum Anatomy 0.000 abstract description 10
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 7
- 230000000062 effect on obesity Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 39
- 241000894006 Bacteria Species 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000037396 body weight Effects 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 description 7
- 238000013116 obese mouse model Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 241001655328 Bifidobacteriales Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 241000193454 Clostridium beijerinckii Species 0.000 description 2
- 241000193171 Clostridium butyricum Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 241001495180 Arthrospira Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241001430332 Bifidobacteriaceae Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000266824 Oscillospira Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241001531197 [Eubacterium] hallii Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- -1 nitrogen-containing polysaccharides Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a probiotic composition for preventing and/or treating metabolic diseases, which comprises functional probiotics, wherein the functional probiotics are composed of specific bifidobacteria, can play a role in preventing and/or treating metabolic diseases, has obvious improvement effect on obesity, can improve glucose tolerance and insulin sensitivity, can reduce total cholesterol in serum, and can reduce obesity physiological indexes such as triglyceride in serum. The invention also discloses application of the probiotic composition in preparation of probiotic products for preventing and/or treating metabolic diseases.
Description
Technical Field
The invention belongs to the technical field of probiotics, and particularly relates to a probiotic composition for preventing and/or treating metabolic diseases and application of the probiotic composition in preparation of a probiotic product for preventing and/or treating metabolic diseases.
Background
Currently, the prevalence of obesity continues to rise worldwide, and the World Health Organization (WHO) defines obesity as an abnormal or excessive accumulation of fat that may cause health damage, and is closely related to diseases such as type II diabetes, hypertension, hyperlipidemia, cardiovascular diseases, cirrhosis, and the like. The development of obesity is affected by a variety of factors including genetic factors, hormonal use, dietary, exercise and other environmental factors, and in recent years, more and more studies have demonstrated that obesity occurs in a close and inseparable relationship with the host intestinal flora. It has been found that there is a great difference between intestinal flora of obese patients and healthy persons, and that intestinal flora of obese patients is more abundant than normal persons in intestinal tract than in intestinal flora of obese patients, and that the abundance of bifidobacteria (bifidobacteria), tremella (oscillospira), erwinia (Erwinia), vibrio succinate (succininivibrio) and al Li Peisi (alitispes) is significantly reduced. Modifying the composition and function of the intestinal flora of a patient by dietary intervention or other means to improve obesity and its related metabolic diseases has been an important means of effectively treating obesity in recent years.
Pendulum has evolved the first hypoglycemic probiotic product, pendulum Glucose Control (PGC), month 6 of 2020. PGCs contained Akkermansia muciniphila WB-STR-0001 (abbreviated AKK bacteria), eubacterium hallii WB-STR-0008 (Clostridium cholerae), clostridium butyricum WB-STR-0006 (Clostridium butyricum), clostridium beijerinckii WB-STR-0005 (Clostridium beijerinckii), bifidobacterium infantis 100 (Bifidobacterium infantis) 5 strains and inulin 1 prebiotics in a randomized, double-blind placebo control study. Type II diabetics, compared to placebo, had a 0.6% drop in A1C and a 32.5% drop in peak blood glucose (AUC) after 12 weeks of PGC administration.
More and more researches prove that the intestinal probiotics can obviously improve metabolic diseases such as obesity, diabetes and the like through a plurality of modes such as changing the composition of intestinal bacteria, strengthening intestinal barrier, regulating intestinal immunity and the like. For example, the PGC probiotic combination can well supplement the human body with the missing strain in the patient, and restore the micro-ecological environment of human intestinal health. However, the intestinal flora of the crowd has great difference in various factors such as regions, race, environment and the like, and the foreign probiotic products are not necessarily suitable for Chinese residents.
The invention aims at developing functional probiotics which are suitable for Chinese people and can play a role in preventing and/or treating metabolic diseases.
Disclosure of Invention
In view of the above, it is desirable to provide a probiotic composition for the prevention and/or treatment of metabolic diseases, comprising functional probiotics, involving one or more bifidobacteria. The probiotics with specified functions are used as active ingredients, have obvious effects in preventing and/or treating metabolic diseases, have obvious improvement effect on obesity, can improve glucose tolerance and insulin sensitivity, reduce total cholesterol in serum, and reduce physiological indexes of obesity such as triglyceride in serum.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
the invention provides a probiotic composition for preventing and/or treating metabolic diseases, which comprises any one or a combination of more than two of the strains (1) - (5):
(1) The first bifidobacterium faecalis (Bifidobacterium faecalis) has a preservation number of CCTCC M2022037;
(2) The second bifidobacterium faecalis (Bifidobacterium faecalis) has a preservation number of CCTCC M2022038;
(3) Bifidobacterium longum (Bifidobacterium longum) with a preservation number of CCTCC M2022039;
(4) Bifidobacterium pseudocatenulatum (Bifidobacterium pseudochain) with a preservation number of CCTCC M2022040;
(5) Bifidobacterium bifidum (Bifidobacterium bifidum) with a preservation number of CCTCC M2022041;
or at least one of a bacterial strain having at least 98% genomic sequence identity with any one of the strains described in (1) - (5) or a bacterial strain having at least 95% 16S rRNA identity with any one of the strains described in (1) - (5).
Further, in the probiotic composition, the ratio of the number of cells of the first bifidobacterium faecalis, the second bifidobacterium faecalis, the bifidobacterium longum, the bifidobacterium pseudocatenulatum and the bifidobacterium bifidum is (1-10): (1-10): (1-10): (1-10): (1-10).
Further aspects, the probiotic composition further comprises a prebiotic ingredient.
The invention further provides the use of a probiotic composition as described in any of the preceding claims in the manufacture of a medicament for the prophylaxis and/or treatment of metabolic disorders.
Further, the metabolic disease comprises obesity or type II diabetes.
The invention further provides a medicament for preventing and/or treating metabolic diseases, which comprises the probiotic composition as described in any one of the preceding claims and a pharmaceutically acceptable carrier, auxiliary material or additive.
Further, the medicament is a capsule, a tablet, a granule, a suspension, a powder or a diluent.
Further, in the medicine, the concentration of the thallus is 10 8 -10 11 CFU。
The invention further provides an application of the probiotic composition in preparing foods, beverages or health care products.
The invention has the following beneficial effects:
the bacterial strain involved in the probiotic composition is obtained by separating from intestinal tracts of healthy human bodies, and the probiotic composition has high safety.
The probiotic composition can colonize the intestinal tract and thus function for a long period of time.
In addition, the experiment result shows that the probiotic composition has good treatment effect on obesity, can improve glucose tolerance and insulin sensitivity, reduce total cholesterol in serum, reduce triglyceride and other obesity physiological indexes in serum, and has excellent effect in preventing and/or treating metabolic diseases.
Description of biological preservation
Bifidobacterium faecalis zhuliab-2%Bifidobacterium faecaliszhula-2), the strain number is CCTCC M2022037, the preservation time is 2022, 1 month and 10 days, the preservation place is China center for type culture collection, the specific address is the eight-path 299 of the Wuchang district of Wuhan, hubei province, and the biological preservation number is CCTCC M2022037;
bifidobacterium faecalis zhuliab-3%Bifidobacterium faecaliszhula-3), the strain number is CCTCC M2022038, the preservation time is 2022, 1 month and 10 days, the preservation place is China center for type culture collection, the specific address is the eight-path 299 of the Wuchang district of Wuhan, hubei province, and the biological preservation number is CCTCC M2022038;
bifidobacterium longum zhuliab-4%Bifidobacterium longumzhula-4), the strain number is CCTCC M2022039, the preservation time is 2022, 1 month and 10 days, the preservation place is China center for type culture collection, the specific address is the eight-path 299 of the Wuchang district of Wuhan, hubei province, and the biological preservation number is CCTCC M2022039;
bifidobacterium pseudocatenulatum zhuliab-5%Bifidobacterium pseudochainzhula-5), the strain number is CCTCC M2022040, the preservation time is 2022, 1 month and 10 days, the preservation place is China center for type culture collection, the specific address is the eight-path 299 of the Wuchang district of Wuhan, hubei province, and the biological preservation number is CCTCC M2022040;
bifidobacterium bifidum zhuliab-6%Bifidobacterium bifidumzhula-6), the strain number is CCTCC M2022041, the preservation time is 2022, 1 month and 10 days, the preservation place is China center for type culture collection, the specific address is the eight-path 299 of the Wuchang district of Wuhan, hubei province, and the biological preservation number is CCTCC M2022041.
Drawings
Fig. 1 is a graph of the weight change trend of the mice in example 4, in which:P<0.05，**：P<0.05；
fig. 2 is a graph showing the change in blood glucose in the glucose tolerance test of the mice in example 4:P<0.05，**：P<0.05；
FIG. 3 is a schematic view ofThe mice in example 4 showed changes in blood glucose in insulin sensitivity tests, shown in the figure:P<0.05；
fig. 4 is a graph showing the trend of body weight change of obese mice in example 5, wherein:P<0.05，**：P<0.05，***：P<0.005；
fig. 5 is a graph showing the change in blood glucose in the glucose tolerance test of the obese mice of example 5:P<0.05，**：P<0.05；
FIG. 6 is a graph showing the change in blood glucose in insulin sensitivity test in obese mice according to example 5;
FIG. 7 is the content of triglycerides in serum at the end of the experiment in obese mice of example 5;
FIG. 8 is the total cholesterol content in serum at the end of the experiment for obese mice in example 5.
Detailed Description
In order that the invention may be readily understood, a more particular description of the invention will be rendered by reference to specific embodiments that are illustrated below. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The first aspect of the present invention provides a probiotic composition for use in the prevention and/or treatment of metabolic diseases, comprising a specific functional probiotic, in particular, according to an embodiment of the present invention, the functional probiotic may be any one of the strains described in (1) - (5) or a combination of two or more thereof:
(1) The first bifidobacterium faecalis (Bifidobacterium faecalis) is provided with a laboratory number of zhula-002, a preservation number of CCTCC M2022037, and a 16sDNA sequence of the first bifidobacterium faecalis is shown as SEQ ID NO. 1;
(2) The second bifidobacterium faecalis (Bifidobacterium faecalis) has a laboratory number of zhula-003 and a preservation number of CCTCC M2022038, and the 16sDNA sequence of the second bifidobacterium faecalis is shown as SEQ ID NO. 2;
(3) Bifidobacterium longum (Bifidobacterium longum), the laboratory number is zhula-004, the preservation number is CCTCC M2022039, and the 16sDNA sequence is shown as SEQ ID NO. 3;
(4) Bifidobacterium pseudocatenulatum (Bifidobacterium pseudochain), the laboratory number is zhula-005, the preservation number is CCTCC M2022040, and the 16sDNA sequence is shown as SEQ ID NO. 4;
(5) Bifidobacterium bifidum (Bifidobacterium bifidum), the laboratory number is zhula-006, the preservation number is CCTCC M2022041, and the 16sDNA sequence is shown as SEQ ID NO. 5.
In further embodiments of the invention, the functional probiotic may be at least one of the bacterial strains having at least 98% genomic sequence identity with any one of the strains described in (1) - (5), e.g. the genomic sequence identity may be 98%, 98.5%, 99%, 99.5% or 100%, preferably the genomic sequence identity is above 99%; the functional probiotic may also be at least one of the bacterial strains having at least 95% 16S rRNA identity with any of the strains described in (1) - (5), e.g. the 16S rRNA identity may be 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5% or 100%, preferably the 16S rRNA identity is above 97%. It should be noted that the alignment of genomic sequence identity or 16S rRNA identity described herein is well known in the art and will not be specifically described herein.
It will be appreciated that the functional probiotic bacteria in the probiotic compositions described herein for use in the prevention and/or treatment of metabolic disorders may be any of the strains described above, or may be a combination of any two or more of the strains in any cell ratio.
"probiotic" as used herein means a microorganism having specificity that, when swallowed or applied in sufficient quantity, is capable of inducing a functional and beneficial effect specific to the host's health condition in the user. The most commonly used probiotics at present mainly comprise lactobacillus and Bifidobacterium, wherein the Bifidobacterium is a gram positive bacterium of bifidobacteriaceae of bifidobacteriales, namely a plurality of bifidobacteria of the bifidobacteriales are involved in the process of separating the functional probiotics from healthy human intestinal tracts, specifically, taking feces of healthy volunteers as samples, separating and culturing the samples, determining the species by combining a PCR (polymerase chain reaction) amplification technology with 16s rRNA sequencing analysis, and finally screening the samples in vitro to obtain the functional probiotics. The invention takes the functional probiotics as an active ingredient to form a probiotic composition, coordinates the actions among probiotics and microorganisms, and achieves obvious effects in preventing and/or treating metabolic diseases.
Preferably, in some specific embodiments of the present invention, the functional probiotics in the probiotic composition are obtained by mixing the five probiotics according to any cell number ratio, and further preferably, the cell number ratio of the first bifidobacterium faecalis, the second bifidobacterium faecalis, the bifidobacterium longum, the pseudobifidobacterium catenulatum and the bifidobacterium bifidum is (1-10): (1-10): (1-10): (1-10): (1-10), more preferably, the ratio of the number of cells of the first bifidobacterium faecalis, the second bifidobacterium faecalis, the bifidobacterium longum, the bifidobacterium pseudocatenulatum and the bifidobacterium bifidum is 1:1:1:1:1.
further, the probiotic composition further comprises a prebiotic ingredient, herein "prebiotic" means a dietary substance or ingredient (such as fiber, etc.), which is neither digested nor absorbed by the body, and which, when intact in the colon, selectively stimulates the growth and activity of a flora beneficial to the health of the individual. In some embodiments of the present invention, the prebiotic is preferably a carbohydrate that is not digested and absorbed by the body, and specific examples that may be mentioned include, but are not limited to, fructooligosaccharides, galactooligosaccharides, xylooligosaccharides, isomaltooligosaccharides, soy oligosaccharides, inulin, spirulina, arthrospira, etc., and furthermore, polysaccharides (e.g., coriolus versicolor polysaccharide, nitrogen-containing polysaccharides of the beancurd, etc.), protein hydrolysates (e.g., hydrolysates of casein, alpha-lactalbumin, lactoferrin, etc.), and vegetables, herbs, wild plants in natural plants, etc. It will be appreciated that the prebiotic composition may be selected by those skilled in the art based on the actual circumstances and will not be described in detail herein.
In a second aspect the present invention provides the use of a probiotic composition according to the first aspect of the invention for the preparation of a probiotic product for the prevention and/or treatment of metabolic disorders.
Among these, the "metabolic diseases" described herein mainly include:
(i) Obesity and obesity-related disorders
(ii) Type II diabetes.
The term "probiotic product" as used herein means a medicament comprising as active ingredient a probiotic composition according to the first aspect of the invention.
In a third aspect, the present invention provides a probiotic product for the prevention and/or treatment of metabolic diseases, comprising a probiotic composition according to the first aspect of the present invention and a pharmaceutically acceptable carrier, adjuvant or additive, wherein the "carrier", "adjuvant" or "additive" is selected conventionally in the art according to the drug, and is not specifically described herein.
In some embodiments of the invention, the medicament may be a formulation, and the probiotic composition may be formulated in admixture with suitable excipients, such as dispersing agents, sweeteners, stabilizers, preservatives and the like, such as amino acids, vitamins or enzymes and the like, as are commonly used in the formulation or pharmaceutical arts.
The medicine of the invention can be oral capsules, suspensions, tablets, granules or powder; can be made in coated, encapsulated or microencapsulated form to resist gastric erosion; can also be made in a sustained release form for the selective release of the active ingredient in the intestine, in particular in the colon; in addition, in some preferred embodiments of the present invention, the functional probiotics described above may also be mixed and lyophilized with suitable excipients using techniques and equipment commonly used for drug lyophilization processes, etc., as the preparation of the drug may be carried out by means conventional in the art and will not be specifically described herein.
Further, the specific application dose can be adjusted according to the actual situation, and in some preferred embodiments of the present invention, the total cell concentration in the drug is 1×10 8 -1×10 11 CFU; more preferably, the cell concentration is 1X 10 9 Or 1X 10 10 CFU。
Further, the invention provides the use of a probiotic composition as described above in the preparation of a food, beverage or health product.
The present invention will be illustrated by the following examples, which are given for illustrative purposes only and are not intended to limit the scope of the present invention in any way, and unless otherwise specified, the conditions or procedures not specifically described are conventional and the reagents and materials employed are commercially available.
EXAMPLE 1 isolation of functional bacteria
Collecting faeces of 10 healthy volunteers, storing in 20% glycerophosphate buffer, and respectively gradient diluting faeces to 10 -5 、10 -6 、10 -7 ；
Each concentration was plated on MRS broth (Solarbio M8540), and cultured anaerobically at 37℃for 48 hours;
monoclonal was picked up and cultured in MRS broth and PCR amplified by 16sRNA universal primer (upstream primer 27F:AGAGTTTG ATCCTGGCTCAG, downstream primer 1492R:GGTTA CCTTGTTACGACTT);
sequencing the amplified product, comparing the 16s RNA sequences to determine species, and preserving the strain at-80 ℃ by glycerol; and selecting bifidobacteria from the separated strains for in vitro screening to finally obtain five potential functional probiotics which are respectively coded as bifidobacterium faecalis zhulob-002, bifidobacterium faecalis zhulob-003, bifidobacterium longum zhulob-004, bifidobacterium pseudocatenulatum zhulob-005 and bifidobacterium bifidum zhulob-006.
EXAMPLE 2 cultivation of functional bacteria
The culture method of the five functional probiotics is consistent, and specifically comprises the following steps: the functional probiotics obtained in frozen example 1 were taken out from a refrigerator at-80℃and streaked in MRS broth, cultured anaerobically at 37℃until significant monoclonals appeared, and the monoclonals were picked up into 12ml culture tubes, subjected to liquid culture in MRS broth until the OD600 value was 1.0-2.0, centrifuged at 3000rpm for 10 minutes, and bacterial cells were collected.
EXAMPLE 3 preparation of Mixed functional bacteria combination preparation
Obtaining bacterial cells cultured in example 2, 2X 10 cells were taken respectively 8 Bacterial suspension of CFU was centrifuged at 3000rpm for 10 minutes, supernatant of bacterial solution was removed, and resuspension was performed with 200. Mu.l of sterile phosphate buffer, five bacteria were added according to cell number ratio of 1:1:1:1:1, mixing in a mode of 3000rpm for 10 minutes, and collecting mixed thalli;
sterile water configured to contain a prebiotic;
the mixed bacteria collected after centrifugation are resuspended to 200 μl with sterile water containing prebiotics, and the mixed functional bacteria combination preparation used for animal experiments is prepared.
Example 4 validation of Mixed functional bacteria combination preparations to improve obesity in mice
(1) The method comprises the steps of dividing 18 SPF grade C57/B6j mice (purchased from collecting medicine) of 8-10 weeks into three groups, wherein one group is a control group (6), one group is an experimental group 1 (6), one group is an insulin (1 IU/kg) positive control group (6), feeding high-fat foods (Meissen, MD12033, 60% fat kcal) respectively from day 0 after the environment adaptation, simultaneously, adding sterile water to the control group in a gastric lavage mode, and adding a mixed functional bacteria combined preparation to the experimental group 1, wherein the gastric lavage frequency is once every two days, and the number of the gastric lavage mixed functional bacteria combined preparations is 1×10 9 CFU。
The body weight was monitored weekly, taking the initial body weight as 100%, and weekly relative body weight = real-time body weight/initial body weight x 100%, and a body weight curve was drawn using the relative body weight. The results are shown in fig. 1, and the experimental results show that the weight growth rate of the mice in the experimental group 1 is obviously reduced compared with that of the mice in the control group, so that the mixed functional bacteria combined preparation can obviously control the weight growth of the mice.
(2) The glucose tolerance assay of the mice was performed at week 10. Specifically, mice were fasted overnight (12-16 hours), the body weight of the mice was weighed, the amount of glucose required for the mice was calculated at a dose of 1.5g/kg, blood was taken from the tail of the mice at 0 minutes, and the fasting blood glucose values of the mice were measured with a blood glucose test paper. After the mice were allowed to stand for 30 minutes, the corresponding glucose doses were given to each mouse by gavage in the order of number. Starting from the time of gastric lavage of the mice, the blood glucose values of the mice were measured again after 15 minutes, 30 minutes, 60 minutes, and 90 minutes, and the changes in the blood glucose values of the mice were plotted to indicate the tolerance of the mice to glucose. The results are shown in fig. 2, and the experimental results show that the glucose tolerance of the mice in the experimental group 1 treated with the mixed functional bacteria combination preparation is significantly better than that of the mice in the control group.
(3) Insulin sensitivity testing was performed at week 12. Specifically, the mice were fasted for 3-4 hours, the body weight of the mice was weighed, the amount of insulin required for the mice was calculated at a dose of 1U/kg, blood was taken from the tail of the mice at 0 minutes, and the fasting blood glucose values of the mice were measured with a blood glucose test paper. After the mice were allowed to stand for 30 minutes, insulin was administered to each of the mice by intraperitoneal injection in the order of number. Starting from the time when the mice received insulin injections, the blood glucose levels of the mice were measured again at 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, and changes in blood glucose levels of the mice were plotted to indicate the sensitivity of the mice to insulin. The results are shown in fig. 3, and the experimental results show that the insulin sensitivity of the mice in the experimental group 1, which were treated with the mixed functional bacterial combination preparation, was improved to some extent relative to the control group.
Example 5 validation of the Effect of Mixed functional bacteria combination preparations on obese mice
The number of SPF class C57/B6j mice (purchased from Ji Cui Ji Kangxi) of 18 age of 8-10 weeks is divided into three groups, one group is a control group (6),One group was experimental group 1 (6) and one group was positive control group (6) of liraglutide (0.02 mg/kg), and after the adaptation to the environment, feeding with high fat diet (midison, MD12033, 60% fat kcal) was started at week-10 until the body weight reached about 40 g. The sterile water is administered to the control group by means of gastric lavage at week 0, the combined functional bacteria preparation is administered to the experimental group 1, and the gastric lavage frequency is once every two days, wherein the number of the combined functional bacteria preparations for gastric lavage of the experimental group 1 is 1×10 9 CFU. The body weight was monitored weekly, calculated and counted in the same manner as in example 4, and the results are shown in fig. 4.
The glucose tolerance assay of the mice was performed at week 15 and the insulin sensitivity test was performed at week 18, the method being consistent with example 4 and the results being shown in figures 5 and 6.
The measurement of triglyceride and total cholesterol was performed at week 20, specifically, 500-600. Mu.l of mouse blood was obtained by taking blood from the eyeball, and after standing for 30 minutes, the upper layer mouse serum was taken and measured using a Triglyceride (TG) test kit (Nanjin, A110-1-1) and a total cholesterol (T-CHO) test kit (Nanjin, A111-1-1), and the results are shown in FIGS. 7 and 8.
As can be seen from the results in fig. 4-8, the weight gain of mice in experimental group 1 of the gastric lavage mixed functional bacteria combined preparation is significantly reduced; the glucose tolerance of the mice in the experimental group 1 is obviously better than that of the mice in the control group, and the insulin sensitivity is improved to a certain extent; in addition, the serum triglyceride and total cholesterol content of the mice in the experimental group 1 are somewhat reduced compared with the control group. The experimental results show that the mixed functional bacteria combined preparation has therapeutic effect on obese mice.
The above examples illustrate only a few embodiments of the invention, which are described in detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
SEQUENCE LISTING
<110> university of science and technology of China
<120> probiotic composition for preventing and/or treating metabolic diseases and use thereof
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 1273
<212> DNA
<213> unknown
<400> 1
ggtcgcgtcc tatcagcttg atggcggggt aacggcccac catggcttcg acgggtagcc 60
ggcctgagag ggcgaccggc cacattggga ctgagatacg gcccagactc ctacgggagg 120
cagcagtggg gaatattgca caatgggcgc aagcctgatg cagcgacgcc gcgtgcggga 180
tgacggcctt cgggttgtaa accgcttttg actgggagca agcccttcgg ggtgagtgta 240
cctttcgaat aagcaccggc taactacgtg ccagcagccg cggtaatacg tagggtgcaa 300
gcgttatccg gaattattgg gcgtaaaggg ctcgtaggcg gttcgtcgcg tccggtgtga 360
aagtccatcg cttaacggtg gatccgcgcc gggtacgggc gggcttgagt gcggtagggg 420
agactggaat tcccggtgta acggtggaat gtgtagatat cgggaagaac accaatggcg 480
aaggcaggtc tctgggccgt cactgacgct gaggagcgaa agcgtgggga gcgaacagga 540
ttagataccc tggtagtcca cgccgtaaac ggtggatgct ggatgtgggg accattccac 600
ggtctccgtg tcggagccaa cgcgttaagc atcccgcctg gggagtacgg ccgcaaggct 660
aaaactcaaa gaaattgacg ggggcccgca caagcggcgg agcatgcgga ttaattcgat 720
gcaacgcgaa gaaccttacc tgggcttgac atgttcccga cagccgtaga gatacggttt 780
cccttcgggg cgggttcaca ggtggtgcat ggtcgtcgtc agctcgtgtc gtgagatgtt 840
gggttaagtc ccgcaacgag cgcaaccctc gccctgtgtt gccagcacgt cgtggtggga 900
actcacgggg gaccgccggg gtcaactcgg aggaaggtgg ggatgacgtc agatcatcat 960
gccccttacg tccagggctt cacgcatgct acaatggccg gtacaacggg atgcgacact 1020
gtgaggtgga gcggatccct taaaaccggt ctcagttcgg attggagtct gcaacccgac 1080
tccatgaagg cggagtcgct agtaatcgcg gatcagcaac gccgcggtga atgcgttccc 1140
gggccttgta cacaccgccc gtcaagtcat gaaagtgggt agcacccgaa gccggtggcc 1200
caaccttttg gggggaagcc gcttaagggg aaattctgga tgggaattaa gccgaacagg 1260
gaaaacccga aaa 1273
<210> 2
<211> 1496
<212> DNA
<213> unknown
<400> 2
tagggtttcg gatctggctc aggatgaacg ctggcggcgt gcttaacaca tgcaagtcga 60
acgggatccc aggagcttgc tcctgggtga gagtggcgaa cgggtgagta atgcgtgacc 120
gacctgcccc atacaccgga atagctcctg gaaacgggtg gtaatgccgg atgctccagt 180
tgaccgcatg gtcctctggg aaagcttttg cggtatggga tggggtcgcg tcctatcagc 240
ttgatggcgg ggtaacggcc caccatggct tcgacgggta gccggcctga gagggcgacc 300
ggccacattg ggactgagat acggcccaga ctcctacggg aggcagcagt ggggaatatt 360
gcacaatggg cgcaagcctg atgcagcgac gccgcgtgcg ggatgacggc cttcgggttg 420
taaaccgctt ttgactggga gcaagccctt cggggtgagt gtacctttcg aataagcacc 480
ggctaactac gtgccagcag ccgcggtaat acgtagggtg caagcgttat ccggaattat 540
tgggcgtaaa gggctcgtag gcggttcgtc gcgtccggtg tgaaagtcca tcgcttaacg 600
gtggatccgc gccgggtacg ggcgggcttg agtgcggtag gggagactgg aattcccggt 660
gtaacggtgg aatgtgtaga tatcgggaag aacaccaatg gcgaaggcag gtctctgggc 720
cgtcactgac gctgaggagc gaaagcgtgg ggagcgaaca ggattagata ccctggtagt 780
ccacgccgta aacggtggat gctggatgtg gggaccattc cacggtctcc gtgtcggagc 840
caacgcgtta agcatcccgc ctggggagta cggccgcaag gctaaaactc aaagaaattg 900
acgggggccc gcacaagcgg cggagcatgc ggattaattc gatgcaacgc gaagaacctt 960
acctgggctt gacatgttcc cgacagcccc agagatgggg cctcccttcg gggcgggttc 1020
acaggtggtg catggtcgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac 1080
gagcgcaacc ctcgccctgt gttgccagca cgtcgtggtg ggaactcacg ggggaccgcc 1140
ggggtcaact cggaggaagg tggggatgac gtcagatcat catgcccctt acgtccaggg 1200
cttcacgcat gctacaatgg ccggtacaac gggatgcgac accgcgaggt ggagcggatc 1260
ccttaaaacc ggtctcagtt cggattggag tctgcaaccc gactccatga aggcggagtc 1320
gctagtaatc gcggatcagc aacgccgcgg tgaatgcgtt cccgggcctt gtacacaccg 1380
cccgtcaagt catgaaagtg ggtagcaccc gaagccggtg gcccaacctt ttggggggag 1440
ccgtctaagg tgagactcgt gattgggact aagtcgtaaa ggggaacccc gaaatc 1496
<210> 3
<211> 1497
<212> DNA
<213> unknown
<400> 3
attagggttt cgatctggct caggatgaac gctggcggcg tgcttaacac atgcaagtcg 60
aacgggatcc atcaggcttt gcttggtggt gagagtggcg aacgggtgag taatgcgtga 120
ccgacctgcc ccatacaccg gaatagctcc tggaaacggg tggtaatgcc ggatgctcca 180
gttgatcgca tggtcttctg ggaaagcttt cgcggtatgg gatggggtcg cgtcctatca 240
gcttgacggc ggggtaacgg cccaccgtgg cttcgacggg tagccggcct gagagggcga 300
ccggccacat tgggactgag atacggccca gactcctacg ggaggcagca gtggggaata 360
ttgcacaatg ggcgcaagcc tgatgcagcg acgccgcgtg agggatggag gccttcgggt 420
tgtaaacctc ttttatcggg gagcaagcga gagtgagttt acccgttgaa taagcaccgg 480
ctaactacgt gccagcagcc gcggtaatac gtagggtgca agcgttatcc ggaattattg 540
ggcgtaaagg gctcgtaggc ggttcgtcgc gtccggtgtg aaagtccatc gcttaacggt 600
ggatccgcgc cgggtacggg cgggcttgag tgcggtaggg gagactggaa ttcccggtgt 660
aacggtggaa tgtgtagata tcgggaagaa caccaatggc gaaggcaggt ctctgggccg 720
ttactgacgc tgaggagcga aagcgtgggg agcgaacagg attagatacc ctggtagtcc 780
acgccgtaaa cggtggatgc tggatgtggg gcccgttcca cgggttccgt gtcggagcta 840
acgcgttaag catcccgcct ggggagtacg gccgcaaggc taaaactcaa agaaattgac 900
gggggcccgc acaagcggcg gagcatgcgg attaattcga tgcaacgcga agaaccttac 960
ctgggcttga catgttcccg acggtcgtag agatacggct tcccttcggg gcgggttcac 1020
aggtggtgca tggtcgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga 1080
gcgcaaccct cgccccgtgt tgccagcgga ttatgccggg aactcacggg ggaccgccgg 1140
ggttaactcg gaggaaggtg gggatgacgt cagatcatca tgccccttac gtccagggct 1200
tcacgcatgc tacaatggcc ggtacaacgg gatgcgacgc ggcgacgcgg agcggatccc 1260
tgaaaaccgg tctcagttcg gatcgcagtc tgcaactcga ctgcgtgaag gcggagtcgc 1320
tagtaatcgc gaatcagcaa cgtcgcggtg aatgcgttcc cgggccttgt acacaccgcc 1380
cgtcaagtca tgaaagtggg cagcacccga agccggtggc ctaacccctt gtgggatgga 1440
gccgtctaag gtgaggctcg tgattgggac taagtcgtaa cagggaaaac cggaaaa 1497
<210> 4
<211> 1403
<212> DNA
<213> unknown
<400> 4
agtggcgaac gggtgagtaa tgcgtgaccg acctgcccca tacaccggaa tagctcctgg 60
aaacgggtgg taatgccgga tgctccgact cctcgcatgg ggtgtcggga aagatttcat 120
cggtatggga tggggtcgcg tcctatcagg tagtcggcgg ggtaacggcc caccgagcct 180
acgacgggta gccggcctga gagggcgacc ggccacattg ggactgagat acggcccaga 240
ctcctacggg aggcagcagt ggggaatatt gcacaatggg cgcaagcctg atgcagcgac 300
gccgcgtgcg ggatgacggc cttcgggttg taaaccgctt ttgatcggga gcaagccttc 360
gggtgagtgt acctttcgaa taagcaccgg ctaactacgt gccagcagcc gcggtaatac 420
gtagggtgca agcgttatcc ggaattattg ggcgtaaagg gctcgtaggc ggttcgtcgc 480
gtccggtgtg aaagtccatc gcttaacggt ggatctgcgc cgggtacggg cgggctggag 540
tgcggtaggg gagactggaa ttcccggtgt aacggtggaa tgtgtagata tcgggaagaa 600
caccaatggc gaaggcaggt ctctgggccg ttactgacgc tgaggagcga aagcgtgggg 660
agcgaacagg attagatacc ctggtagtcc acgccgtaaa cggtggatgc tggatgtggg 720
gcccgttcca cgggttccgt gtcggagcta acgcgttaag catcccgcct ggggagtacg 780
gccgcaaggc taaaactcaa agaaattgac gggggcccgc acaagcggcg gagcatgcgg 840
attaattcga tgcaacgcga agaaccttac ctgggcttga catgttcccg acagccgtag 900
agatatggcc tcccttcggg gcgggttcac aggtggtgca tggtcgtcgt cagctcgtgt 960
cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct cgccctgtgt tgccagcacg 1020
tcatggtggg aactcacggg ggaccgccgg ggtcaactcg gaggaaggtg gggatgacgt 1080
cagatcatca tgccccttac gtccagggct tcacgcatgc tacaatggcc ggtacaacgg 1140
gatgcgacac ggcgacgtgg agcggatccc tgaaaaccgg tctcagttcg gattggagtc 1200
tgcaacccga ctccatgaag gcggagtcgc tagtaatcgc ggatcagcaa cgccgcggtg 1260
aatgcgttcc cgggccttgt acacaccgcc cgtcaagtca tgaaagtggg tagcacccga 1320
agccggtggc ctaacctttt tggatggagc cgtctaaggt gagactcgtg attgggacta 1380
agtcgaaggg ggaacgcaaa agg 1403
<210> 5
<211> 1406
<212> DNA
<213> unknown
<400> 5
agagtggcga acgggtgagt aatgcgtgac cgacctgccc catgctccgg aatagctcct 60
ggaaacgggt ggtaatgccg gatgttccac atgatcgcat gtgattgtgg gaaagatttc 120
atcggcgtgg gatggggtcg cgtcctatca gcttgttggt gaggtaacgg ctcaccaagg 180
cttcgacggg tagccggcct gagagggcga ccggccacat tgggactgag atacggccca 240
gactcctacg ggaggcagca gtggggaata ttgcacaatg ggcgcaagcc tgatgcagcg 300
acgccgcgtg agggatggag gccttcgggt tgtaaacctc ttttgtttgg gagcaagcct 360
tcgggtgagt gtacctttcg aataagcgcc ggctaactac gtgccagcag ccgcggtaat 420
acgtagggcg caagcgttat ccggatttat tgggcgtaaa gggctcgtag gcggctcgtc 480
gcgtccggtg tgaaagtcca tcgcttaacg gtggatctgc gccgggtacg ggcgggctgg 540
agtgcggtag gggagactgg aattcccggt gtaacggtgg aatgtgtaga tatcgggaag 600
aacaccgatg gcgaaggcag gtctctgggc cgtcactgac gctgaggagc gaaagcgtgg 660
ggagcgaaca ggattagata ccctggtagt ccacgccgta aacggtggac gctggatgtg 720
gggcacgttc cacgtgttcc gtgtcggagc taacgcgtta agcgtcccgc ctggggagta 780
cggccgcaag gctaaaactc aaagaaattg acgggggccc gcacaagcgg cggagcatgc 840
ggattaattc gatgcaacgc gaagaacctt acctgggctt gacatgttcc cgacgacgcc 900
agagatggcg tttcccttcg gggcgggttc acaggtggtg catggtcgtc gtcagctcgt 960
gtcgtgagat gttgggttaa gtcccgcaac gagcgcaacc ctcgccccgt gttgccagca 1020
cgttatggtg ggaactcacg ggggaccgcc ggggttaact cggaggaagg tggggatgac 1080
gtcagatcat catgcccctt acgtccaggg cttcacgcat gctacaatgg ccggtacagc 1140
gggatgcgac atggcgacat ggagcggatc cctgaaaacc ggtctcagtt cggatcggag 1200
cctgcaaccc ggctccgtga aggcggagtc gctagtaatc gcggatcagc aacgccgcgg 1260
tgaatgcgtt cccgggcctt gtacacaccg cccgtcaagt catgaaagtg ggcagcaccc 1320
gaagccggtg gcctaacccc ttgtgggatg gagccgtcta aggtgaggct cgtgattggg 1380
actaagtcga aggggggtcg gcaaac 1406
Claims (4)
1. A probiotic composition for use in the prevention and/or treatment of a metabolic disorder, which is obesity or type II diabetes, characterized in that the probiotic composition consists of the following five strains (1) - (5) and prebiotic ingredients:
(1) The first bifidobacterium faecalis (Bifidobacterium faecalis) has a preservation number of CCTCC M2022037;
(2) The second bifidobacterium faecalis (Bifidobacterium faecalis) has a preservation number of CCTCC M2022038;
(3) Bifidobacterium longum (Bifidobacterium longum) with a preservation number of CCTCC M2022039;
(4) Bifidobacterium pseudocatenulatum (Bifidobacterium pseudochain) with a preservation number of CCTCC M2022040;
(5) Bifidobacterium bifidum (Bifidobacterium bifidum) with a preservation number of CCTCC M2022041;
in the probiotic composition, the ratio of the cell numbers of the first bifidobacterium faecalis, the second bifidobacterium faecalis, the bifidobacterium longum, the bifidobacterium pseudocatenulatum and the bifidobacterium bifidum is 1:1:1:1:1, the number of the bacterial cells is 10 8 -10 11 CFU。
2. Use of a probiotic composition according to claim 1 for the manufacture of a medicament for the prevention and/or treatment of a metabolic disease, which is obesity or type II diabetes.
3. A medicament for preventing and/or treating a metabolic disease, which is obesity or type II diabetes, comprising the probiotic composition of claim 1 and pharmaceutically acceptable excipients; in the medicine, the number of the thalli is 10 8 -10 11 CFU。
4. A medicament according to claim 3, wherein the medicament is in the form of a capsule, tablet, granule or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210122665.4A CN115466689B (en) | 2022-02-09 | 2022-02-09 | Probiotic composition for preventing and/or treating metabolic diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210122665.4A CN115466689B (en) | 2022-02-09 | 2022-02-09 | Probiotic composition for preventing and/or treating metabolic diseases and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115466689A CN115466689A (en) | 2022-12-13 |
| CN115466689B true CN115466689B (en) | 2023-06-16 |
Family
ID=84364175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210122665.4A Active CN115466689B (en) | 2022-02-09 | 2022-02-09 | Probiotic composition for preventing and/or treating metabolic diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115466689B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091152A1 (en) * | 2018-02-13 | 2019-08-22 | Proviva Pharma Inc. | Probiotic formulations for the treatment and alleviation of metabolic and oxidative stress, inflammation and neurodegeneration |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104630096A (en) * | 2014-12-16 | 2015-05-20 | 河北一然生物科技有限公司 | Bifidobacterium bifidum strain TMC3115 with fat suppression cells and application therepof |
| KR20180056972A (en) * | 2016-11-21 | 2018-05-30 | 한국식품연구원 | Composition comprising a strain having formic acid producing ability for the preventing or treatment of obesity, or obesity-realated metabolic syndrome |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2729765T3 (en) * | 2009-06-19 | 2019-11-06 | Dupont Nutrition Biosci Aps | Bifidobacteria for the treatment of congestive heart failure |
| ES2389547B1 (en) * | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | BIFIDOBACTERIUM CECT 7765 AND ITS USE IN THE PREVENTION AND / OR TREATMENT OF OVERWEIGHT, OBESITY AND ASSOCIATED PATHOLOGIES. |
| CA3092318A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| RU2740096C2 (en) * | 2015-12-11 | 2021-01-11 | Элиментари Хелт Лимитед | Bifidobacterium longum for treating obesity and related metabolic disorders |
| KR20180049731A (en) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | Composition for preventing or treating obesity and lipid-related metabolic disease |
| US11660321B2 (en) * | 2017-01-31 | 2023-05-30 | University-Industry Cooperation Group Of Kyung Hee University | Method of treatment with lactic acid bacteria |
| WO2019038449A1 (en) * | 2017-08-25 | 2019-02-28 | University College Cork - National University Of Ireland, Cork | Bifidobacterium longum for treating obesity and weight management |
| CN112672749A (en) * | 2018-04-11 | 2021-04-16 | 韩国生命工学研究院 | Novel Bifidobacterium longum strain or Lactobacillus rhamnosus strain having obesity preventing or treating effect and use thereof |
-
2022
- 2022-02-09 CN CN202210122665.4A patent/CN115466689B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104630096A (en) * | 2014-12-16 | 2015-05-20 | 河北一然生物科技有限公司 | Bifidobacterium bifidum strain TMC3115 with fat suppression cells and application therepof |
| KR20180056972A (en) * | 2016-11-21 | 2018-05-30 | 한국식품연구원 | Composition comprising a strain having formic acid producing ability for the preventing or treatment of obesity, or obesity-realated metabolic syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115466689A (en) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2650002A1 (en) | Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies | |
| TWI594758B (en) | Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof | |
| JP6843140B2 (en) | Bifidobacterium longum for the treatment of obesity and related metabolic disorders | |
| BR112012011315B1 (en) | Formulation comprising probiotic bifidobacteria strain | |
| JP2009511469A (en) | Probiotics affecting fat metabolism and obesity | |
| EP3387156B1 (en) | Lactobacillus casei for treating obesity and associated metabolic disorders | |
| CN102935092A (en) | Novel lactobacilli and composition thereof, and application thereof in preparing medicines used for ameliorating diabetes and complications thereof | |
| CN106994134B (en) | Application of intestinal probiotics in prevention and/or treatment of diabetes and related diseases thereof | |
| Kolida et al. | Gastrointestinal microflora: probiotics | |
| US20150297646A1 (en) | Use of a Lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance | |
| CN115466689B (en) | Probiotic composition for preventing and/or treating metabolic diseases and application thereof | |
| WO2020223180A1 (en) | Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same | |
| US20200376044A1 (en) | Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics | |
| CN116622587B (en) | Probiotic prepared by synthetic biological method, composition and application thereof | |
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| KR101238836B1 (en) | Phamaceutical or food composition for treating or preventing obesity disease comprising a mixture of lactic acid bacteria | |
| US20220192246A1 (en) | Composition and method for synbiotics supplement containing probiotics, digestive enzymes, prebiotics, yeast, protein, b vitamins, and flavoring agent | |
| CN113939281A (en) | Microbial compositions and methods for increasing tolerance and extending shelf life | |
| NL2030011B1 (en) | Prevention or treatment of hepatic steatosis | |
| CN110839693A (en) | Application of parabacteroides gibsonii in preventing or treating obesity or related diseases | |
| CN106974939B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| CN115998777B (en) | Use of lactobacillus paracasei 207-27 | |
| CN111172054B (en) | Lactobacillus casei combined preparation and application thereof | |
| CN115466687A (en) | Composition for reducing body fat content and body weight and application thereof | |
| WO2023178194A2 (en) | Novel microbial composition and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |